Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 185

1.

Clinical and Biological Concepts for Mastering Immune Reconstitution After HSCT: Toward Practical Guidelines and Greater Harmonization.

Kuball J, Boelens JJ.

In: Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies [Internet]. 7th edition. Cham (CH): Springer; 2019. Chapter 10.

2.

A semi-mechanistic model based on glutathione depletion to describe intra-individual reduction in busulfan clearance.

Langenhorst JB, Boss J, van Kesteren C, Lalmohamed A, Kuball J, Egberts ACG, Boelens JJ, Huitema ADR, van Maarseveen EM.

Br J Clin Pharmacol. 2020 Feb 18. doi: 10.1111/bcp.14256. [Epub ahead of print]

PMID:
32067250
3.

Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel.

Bonifazi F, Rubio MT, Bacigalupo A, Boelens JJ, Finke J, Greinix H, Mohty M, Nagler A, Passweg J, Rambaldi A, Socie G, Solano C, Walker I, Barosi G, Kröger N.

Bone Marrow Transplant. 2020 Jan 22. doi: 10.1038/s41409-020-0792-x. [Epub ahead of print]

PMID:
31969678
4.

Metachromatic leukodystrophy and transplantation: remyelination, no cross-correction.

Wolf NI, Breur M, Plug B, Beerepoot S, Westerveld ASR, van Rappard DF, de Vries SI, Kole MHP, Vanderver A, van der Knaap MS, Lindemans CA, van Hasselt PM, Boelens JJ, Matzner U, Gieselmann V, Bugiani M.

Ann Clin Transl Neurol. 2020 Feb;7(2):169-180. doi: 10.1002/acn3.50975. Epub 2020 Jan 22.

5.

A "No-Touch" Antibody-Staining Method of Adherent Cells for High-Throughput Flow Cytometry in 384-Well Microplate Format for Cell-Based Drug Library Screening.

Cornel AM, Szanto CL, van Til NP, van Velzen JF, Boelens JJ, Nierkens S.

Cytometry A. 2019 Dec 26. doi: 10.1002/cyto.a.23956. [Epub ahead of print]

PMID:
31876358
6.

Genetic Susceptibility to Hepatic Sinusoidal Obstruction Syndrome in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation.

Ansari M, Petrykey K, Rezgui MA, Del Vecchio V, Cortyl J, Ralph RO, Nava T, Beaulieu P, St-Onge P, Jurkovic Mlakar S, Huezo-Diaz Curtis P, Uppugunduri CRS, Lesne L, Théoret Y, Chalandon Y, Bartelink IH, Boelens JJ, Bredius RGM, Dalle JH, Lewis V, Kangarloo BS, Peters C, Sinnett D, Bittencourt H, Krajinovic M; Pediatric Disease Working Party of the European Society for Blood and Marrow Transplantation.

Biol Blood Marrow Transplant. 2019 Nov 29. pii: S1083-8791(19)30832-8. doi: 10.1016/j.bbmt.2019.11.026. [Epub ahead of print]

PMID:
31790828
7.

Longitudinal Analysis of Ocular Disease in Children with Mucopolysaccharidosis I after Hematopoietic Cell Transplantation.

van den Broek BTA, van Egmond-Ebbeling MB, Achterberg JA, Boelens JJ, Vlessert IC, Prinsen HCMT, van Doorn J, van Hasselt PM.

Biol Blood Marrow Transplant. 2019 Nov 29. pii: S1083-8791(19)30831-6. doi: 10.1016/j.bbmt.2019.11.025. [Epub ahead of print]

PMID:
31786241
8.

Hematopoietic Stem Cell Transplantation in Inborn Errors of Metabolism.

Tan EY, Boelens JJ, Jones SA, Wynn RF.

Front Pediatr. 2019 Oct 25;7:433. doi: 10.3389/fped.2019.00433. eCollection 2019. Review.

9.

Peripheral neuropathy in metachromatic leukodystrophy: current status and future perspective.

Beerepoot S, Nierkens S, Boelens JJ, Lindemans C, Bugiani M, Wolf NI.

Orphanet J Rare Dis. 2019 Nov 4;14(1):240. doi: 10.1186/s13023-019-1220-4. Review.

10.

Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL.

Curran KJ, Margossian SP, Kernan NA, Silverman LB, Williams DA, Shukla N, Kobos R, Forlenza CJ, Steinherz P, Prockop S, Boulad F, Spitzer B, Cancio MI, Boelens JJ, Kung AL, Szenes V, Park JH, Sauter CS, Heller G, Wang X, Senechal B, O'Reilly RJ, Riviere I, Sadelain M, Brentjens RJ.

Blood. 2019 Dec 26;134(26):2361-2368. doi: 10.1182/blood.2019001641.

PMID:
31650176
11.

Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia.

Bejanyan N, Kim S, Hebert KM, Kekre N, Abdel-Azim H, Ahmed I, Aljurf M, Badawy SM, Beitinjaneh A, Boelens JJ, Diaz MA, Dvorak CC, Gadalla S, Gajewski J, Gale RP, Ganguly S, Gennery AR, George B, Gergis U, Gómez-Almaguer D, Vicent MG, Hashem H, Kamble RT, Kasow KA, Lazarus HM, Mathews V, Orchard PJ, Pulsipher M, Ringden O, Schultz K, Teira P, Woolfrey AE, Saldaña BD, Savani B, Winiarski J, Yared J, Weisdorf DJ, Antin JH, Eapen M.

Blood Adv. 2019 Oct 22;3(20):3123-3131. doi: 10.1182/bloodadvances.2019000722.

12.

Related and unrelated donor transplantation for β-thalassemia major: results of an international survey.

Li C, Mathews V, Kim S, George B, Hebert K, Jiang H, Li C, Zhu Y, Keesler DA, Boelens JJ, Dvorak CC, Agarwal R, Auletta JJ, Goyal RK, Hanna R, Kasow K, Shenoy S, Smith AR, Walters MC, Eapen M.

Blood Adv. 2019 Sep 10;3(17):2562-2570. doi: 10.1182/bloodadvances.2019000291.

13.

A dominant activating RAC2 variant associated with immunodeficiency and pulmonary disease.

Smits BM, Lelieveld PHC, Ververs FA, Turkenburg M, de Koning C, van Dijk M, Leavis HL, Boelens JJ, Lindemans CA, Bloem AC, van de Corput L, van Montfrans J, Nierkens S, van Gijn ME, Geerke DP, Waterham HR, Koenderman L, Boes M.

Clin Immunol. 2019 Aug 2:108248. doi: 10.1016/j.clim.2019.108248. [Epub ahead of print] No abstract available.

PMID:
31382036
14.

Pharmacotherapy in Pediatric Hematopoietic Cell Transplantation.

Admiraal R, Boelens JJ.

Handb Exp Pharmacol. 2019 Aug 3. doi: 10.1007/164_2019_247. [Epub ahead of print]

PMID:
31375921
15.

Predictors for Autoimmune Cytopenias after Allogeneic Hematopoietic Cell Transplantation in Children.

Szanto CL, Langenhorst J, de Koning C, Nierkens S, Bierings M, Huitema ADR, Lindemans CA, Boelens JJ.

Biol Blood Marrow Transplant. 2020 Jan;26(1):114-122. doi: 10.1016/j.bbmt.2019.07.022. Epub 2019 Jul 22.

PMID:
31344451
16.

Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes.

Langenhorst JB, van Kesteren C, van Maarseveen EM, Dorlo TPC, Nierkens S, Lindemans CA, de Witte MA, van Rhenen A, Raijmakers R, Bierings M, Kuball J, Huitema ADR, Boelens JJ.

Blood Adv. 2019 Jul 23;3(14):2179-2187. doi: 10.1182/bloodadvances.2018029421.

17.

Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement.

McCune JS, Quinones CM, Ritchie J, Carpenter PA, van Maarseveen E, Yeh RF, Anasetti C, Boelens JJ, Hamerschlak N, Hassan M, Kang HJ, Kanda Y, Paci A, Perales MA, Shaw PJ, Seewaldt VL, Savani BN, Hsieh A, Poon B, Mohty M, Pulsipher MA, Pasquini M, Dupuis LL.

Biol Blood Marrow Transplant. 2019 Sep;25(9):1890-1897. doi: 10.1016/j.bbmt.2019.05.021. Epub 2019 May 25.

PMID:
31136799
18.

Population Pharmacokinetics of Alemtuzumab (Campath) in Pediatric Hematopoietic Cell Transplantation: Towards Individualized Dosing to Improve Outcome.

Admiraal R, Jol-van der Zijde CM, Furtado Silva JM, Knibbe CAJ, Lankester AC, Boelens JJ, Hale G, Etuk A, Wilson M, Adams S, Veys P, van Kesteren C, Bredius RGM.

Clin Pharmacokinet. 2019 Dec;58(12):1609-1620. doi: 10.1007/s40262-019-00782-0.

19.

Bone-marrow derived mesenchymal stromal cells infusion in therapy refractory juvenile idiopathic arthritis patients.

Swart JF, de Roock S, Nievelstein RAJ, Slaper-Cortenbach ICM, Boelens JJ, Wulffraat NM.

Rheumatology (Oxford). 2019 Oct 1;58(10):1812-1817. doi: 10.1093/rheumatology/kez157.

20.

The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia.

Keating AK, Langenhorst J, Wagner JE, Page KM, Veys P, Wynn RF, Stefanski H, Elfeky R, Giller R, Mitchell R, Milano F, O'Brien TA, Dahlberg A, Delaney C, Kurtzberg J, Verneris MR, Boelens JJ.

Blood Adv. 2019 Apr 9;3(7):1118-1128. doi: 10.1182/bloodadvances.2018025908.

21.

Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation.

Scordo M, Bhatt V, Hilden P, Smith M, Thoren K, Cho C, Shah GL, Maloy MA, Papadopoulos EB, Jakubowski AA, Avecilla ST, O'Reilly RJ, Castro-Malaspina H, Tamari R, Shaffer BC, Boelens JJ, Perales MA, Giralt SA.

Biol Blood Marrow Transplant. 2019 Aug;25(8):1526-1535. doi: 10.1016/j.bbmt.2019.02.021. Epub 2019 Mar 1.

PMID:
30831208
22.

Hematopoietic Stem Cell Transplantation for Mucopolysaccharidoses: Past, Present, and Future.

Taylor M, Khan S, Stapleton M, Wang J, Chen J, Wynn R, Yabe H, Chinen Y, Boelens JJ, Mason RW, Kubaski F, Horovitz DDG, Barth AL, Serafini M, Bernardo ME, Kobayashi H, Orii KE, Suzuki Y, Orii T, Tomatsu S.

Biol Blood Marrow Transplant. 2019 Jul;25(7):e226-e246. doi: 10.1016/j.bbmt.2019.02.012. Epub 2019 Feb 14. Review.

PMID:
30772512
23.

Cord-Blood-Stem-Cell-Derived Conventional Dendritic Cells Specifically Originate from CD115-Expressing Precursors.

Plantinga M, de Haar CG, Dünnebach E, van den Beemt DAMH, Bloemenkamp KWM, Mokry M, Boelens JJ, Nierkens S.

Cancers (Basel). 2019 Feb 5;11(2). pii: E181. doi: 10.3390/cancers11020181.

24.

Hematopoietic stem cell transplantation for CD40 ligand deficiency: Results from an EBMT/ESID-IEWP-SCETIDE-PIDTC study.

Ferrua F, Galimberti S, Courteille V, Slatter MA, Booth C, Moshous D, Neven B, Blanche S, Cavazzana M, Laberko A, Shcherbina A, Balashov D, Soncini E, Porta F, Al-Mousa H, Al-Saud B, Al-Dhekri H, Arnaout R, Formankova R, Bertrand Y, Lange A, Smart J, Wolska-Kusnierz B, Aquino VM, Dvorak CC, Fasth A, Fouyssac F, Heilmann C, Hoenig M, Schuetz C, Kelečić J, Bredius RGM, Lankester AC, Lindemans CA, Suarez F, Sullivan KE, Albert MH, Kałwak K, Barlogis V, Bhatia M, Bordon V, Czogala W, Alonso L, Dogu F, Gozdzik J, Ikinciogullari A, Kriván G, Ljungman P, Meyts I, Mustillo P, Smith AR, Speckmann C, Sundin M, Keogh SJ, Shaw PJ, Boelens JJ, Schulz AS, Sedlacek P, Veys P, Mahlaoui N, Janda A, Davies EG, Fischer A, Cowan MJ, Gennery AR; SCETIDE, PIDTC, EBMT & ESID IEWP.

J Allergy Clin Immunol. 2019 Jun;143(6):2238-2253. doi: 10.1016/j.jaci.2018.12.1010. Epub 2019 Jan 17.

25.

Solid organ transplantation after hematopoietic stem cell transplantation in childhood: A multicentric retrospective survey.

Faraci M, Bertaina A, Dalissier A, Ifversen M, Schulz A, Gennery A, Burkhardt B, Badell Serra I, Diaz-de-Heredia C, Lanino E, Lankester AC, Gruhn B, Matthes-Martin S, Kühl JS, Varotto S, Paillard C, Guilmatre A, Sastre A, Abecasis M, Garwer B, Sedlacek P, Boelens JJ, Beohou E, Bader P; EBMT Pediatric Disease Working Party.

Am J Transplant. 2019 Jun;19(6):1798-1805. doi: 10.1111/ajt.15240. Epub 2019 Jan 25.

PMID:
30586230
26.

Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide.

Horwitz ME, Wease S, Blackwell B, Valcarcel D, Frassoni F, Boelens JJ, Nierkens S, Jagasia M, Wagner JE, Kuball J, Koh LP, Majhail NS, Stiff PJ, Hanna R, Hwang WYK, Kurtzberg J, Cilloni D, Freedman LS, Montesinos P, Sanz G.

J Clin Oncol. 2019 Feb 10;37(5):367-374. doi: 10.1200/JCO.18.00053. Epub 2018 Dec 4.

27.

Morbidity and Mortality Associated With Respiratory Virus Infections in Allogeneic Hematopoietic Cell Transplant: Too Little Defense or Harmful Immunity?

Versluys AB, Boelens JJ.

Front Microbiol. 2018 Nov 21;9:2795. doi: 10.3389/fmicb.2018.02795. eCollection 2018. Review.

28.

Allogeneic Haematopoietic Cell Transplantation for Epidermolysis Bullosa: the Dutch Experience.

Gostyńska KB, Yenamandra VK, Lindemans C, Duipmans J, Gostyński A, Jonkman MF, Boelens JJ.

Acta Derm Venereol. 2019 Mar 1;99(3):347-348. doi: 10.2340/00015555-3097. No abstract available.

29.

Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution.

Kellner JN, Delemarre EM, Yvon E, Nierkens S, Boelens JJ, McNiece I, Olson A, Nieto Y, Ciurea S, Popat U, Ahmed S, Champlin R, Ramos J, Nishimoto M, Ma H, Ke Z, Thall P, Khoury JD, Negrin R, Andersson B, Parmar S.

Oncotarget. 2018 Nov 2;9(86):35611-35622. doi: 10.18632/oncotarget.26242. eCollection 2018 Nov 2.

30.

Risk factors affecting outcome of unrelated cord blood transplantation for children with familial haemophagocytic lymphohistiocytosis.

Furtado-Silva JM, Paviglianiti A, Ruggeri A, Boelens JJ, Veys P, Ahmari AA, Zecca M, Locatelli F, Michel G, Volt F, Kenzey C, Sedlacek P, Rao K, Lankester A, Gluckman E, Rocha V; Eurocord/ Monacord, Cord Blood Committee of Cellular Therapy, Immunobiology and Inborn Errors Working Parties of the European Blood and Marrow Transplant Group.

Br J Haematol. 2019 Feb;184(3):397-404. doi: 10.1111/bjh.15642. Epub 2018 Nov 21.

PMID:
30460979
31.

Innate Immune Recovery Predicts CD4+ T Cell Reconstitution after Hematopoietic Cell Transplantation.

de Koning C, Langenhorst J, van Kesteren C, Lindemans CA, Huitema ADR, Nierkens S, Boelens JJ.

Biol Blood Marrow Transplant. 2019 Apr;25(4):819-826. doi: 10.1016/j.bbmt.2018.10.013. Epub 2018 Oct 23.

PMID:
30359735
32.

Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation.

Langenhorst JB, Dorlo TPC, van Maarseveen EM, Nierkens S, Kuball J, Boelens JJ, van Kesteren C, Huitema ADR.

Clin Pharmacokinet. 2019 May;58(5):627-637. doi: 10.1007/s40262-018-0715-9.

33.

Nedd4-Binding Protein 1 and TNFAIP3-Interacting Protein 1 Control MHC-1 Display in Neuroblastoma.

Spel L, Nieuwenhuis J, Haarsma R, Stickel E, Bleijerveld OB, Altelaar M, Boelens JJ, Brummelkamp TR, Nierkens S, Boes M.

Cancer Res. 2018 Dec 1;78(23):6621-6631. doi: 10.1158/0008-5472.CAN-18-0545. Epub 2018 Sep 13.

34.

Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia.

Rice C, Eikema DJ, Marsh JCW, Knol C, Hebert K, Putter H, Peterson E, Deeg HJ, Halkes S, Pidala J, Anderlini P, Tischer J, Kroger N, McDonald A, Antin JH, Schaap NP, Hallek M, Einsele H, Mathews V, Kapoor N, Boelens JJ, Mufti GJ, Potter V, Pefault de la Tour R, Eapen M, Dufour C.

Biol Blood Marrow Transplant. 2019 Mar;25(3):488-495. doi: 10.1016/j.bbmt.2018.08.029. Epub 2018 Sep 5.

PMID:
30194027
35.

Practice pattern changes and improvements in hematopoietic cell transplantation for primary immunodeficiencies.

Marsh RA, Hebert KM, Keesler D, Boelens JJ, Dvorak CC, Eckrich MJ, Kapoor N, Parikh S, Eapen M.

J Allergy Clin Immunol. 2018 Dec;142(6):2004-2007. doi: 10.1016/j.jaci.2018.08.010. Epub 2018 Aug 28. No abstract available.

36.

Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis.

Matlung HL, Babes L, Zhao XW, van Houdt M, Treffers LW, van Rees DJ, Franke K, Schornagel K, Verkuijlen P, Janssen H, Halonen P, Lieftink C, Beijersbergen RL, Leusen JHW, Boelens JJ, Kuhnle I, van der Werff Ten Bosch J, Seeger K, Rutella S, Pagliara D, Matozaki T, Suzuki E, Menke-van der Houven van Oordt CW, van Bruggen R, Roos D, van Lier RAW, Kuijpers TW, Kubes P, van den Berg TK.

Cell Rep. 2018 Jun 26;23(13):3946-3959.e6. doi: 10.1016/j.celrep.2018.05.082.

37.

Salivary α-Iduronidase Activity as a Potential New Biomarker for the Diagnosis and Monitoring the Effect of Therapy in Mucopolysaccharidosis Type I.

van Doorn J, van den Broek BTA, Geboers AJ, Kuiper GA, Boelens JJ, van Hasselt PM.

Biol Blood Marrow Transplant. 2018 Sep;24(9):1808-1813. doi: 10.1016/j.bbmt.2018.06.001. Epub 2018 Jun 13.

38.

Strategies to Genetically Modulate Dendritic Cells to Potentiate Anti-Tumor Responses in Hematologic Malignancies.

Cornel AM, van Til NP, Boelens JJ, Nierkens S.

Front Immunol. 2018 May 18;9:982. doi: 10.3389/fimmu.2018.00982. eCollection 2018. Review.

39.

Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine.

Harris AC, Boelens JJ, Ahn KW, Fei M, Abraham A, Artz A, Dvorak C, Frangoul H, Freytes C, Gale RP, Hong S, Lazarus HM, Loren A, Mineishi S, Nishihori T, O'Brien T, Williams K, Pasquini MC, Levine JE.

Blood Adv. 2018 Jun 12;2(11):1198-1206. doi: 10.1182/bloodadvances.2018016956.

40.

Filgrastim enhances T-cell clearance by antithymocyte globulin exposure after unrelated cord blood transplantation.

de Koning C, Gabelich JA, Langenhorst J, Admiraal R, Kuball J, Boelens JJ, Nierkens S.

Blood Adv. 2018 Mar 13;2(5):565-574. doi: 10.1182/bloodadvances.2017015487.

41.

Human herpesvirus 6 viremia affects T-cell reconstitution after allogeneic hematopoietic stem cell transplantation.

de Koning C, Admiraal R, Nierkens S, Boelens JJ.

Blood Adv. 2018 Feb 27;2(4):428-432. doi: 10.1182/bloodadvances.2017012724.

42.

Slowly Progressive Psychiatric Symptoms: Think Metachromatic Leukodystrophy.

van Rappard DF, de Vries ALC, Oostrom KJ, Boelens JJ, Hollak CEM, van der Knaap MS, Wolf NI.

J Am Acad Child Adolesc Psychiatry. 2018 Feb;57(2):74-76. doi: 10.1016/j.jaac.2017.11.017. No abstract available.

PMID:
29413149
43.

Fine-Tuning Antithymocyte Globulin Dosing and Harmonizing Clinical Trial Design.

Boelens JJ, Admiraal R, Kuball J, Nierkens S.

J Clin Oncol. 2018 Apr 10;36(11):1175-1176. doi: 10.1200/JCO.2017.77.1774. Epub 2018 Feb 7. No abstract available.

PMID:
29412785
44.

Diffusion tensor imaging in metachromatic leukodystrophy.

van Rappard DF, Königs M, Steenweg ME, Boelens JJ, Oosterlaan J, van der Knaap MS, Wolf NI, Pouwels PJW.

J Neurol. 2018 Mar;265(3):659-668. doi: 10.1007/s00415-018-8765-3. Epub 2018 Jan 30.

45.

Use of cord blood derived T-cells in cancer immunotherapy: milestones achieved and future perspectives.

Lo Presti V, Nierkens S, Boelens JJ, van Til NP.

Expert Rev Hematol. 2018 Mar;11(3):209-218. doi: 10.1080/17474086.2018.1431119. Epub 2018 Feb 1. Review.

PMID:
29359983
46.

Early and late outcomes after cord blood transplantation for pediatric patients with inherited leukodystrophies.

van den Broek BTA, Page K, Paviglianiti A, Hol J, Allewelt H, Volt F, Michel G, Diaz MA, Bordon V, O'Brien T, Shaw PJ, Kenzey C, Al-Seraihy A, van Hasselt PM, Gennery AR, Gluckman E, Rocha V, Ruggeri A, Kurtzberg J, Boelens JJ.

Blood Adv. 2018 Jan 4;2(1):49-60. doi: 10.1182/bloodadvances.2017010645. eCollection 2018 Jan 9.

47.

Quality of life of Hurler syndrome patients after successful hematopoietic stem cell transplantation.

Aldenhoven M, van den Broek BTA, Wynn RF, O'Meara A, Veys P, Rovelli A, Jones SA, Parini R, van Hasselt PM, Renard M, Bordon V, de Koning TJ, Boelens JJ.

Blood Adv. 2017 Nov 7;1(24):2236-2242. doi: 10.1182/bloodadvances.2017011387. eCollection 2017 Nov 14. Erratum in: Blood Adv. 2017 Dec 07;1(26):2535.

48.

Low Body Mass Index Is Associated with Increased Risk of Acute GVHD after Umbilical Cord Blood Transplantation in Children and Young Adults with Acute Leukemia: A Study on Behalf of Eurocord and the EBMT Pediatric Disease Working Party.

Paviglianiti A, Dalle JH, Ayas M, Boelens JJ, Volt F, Iori AP, de Souza MP, Diaz MA, Michel G, Locatelli F, Jubert C, Yakoub-Agha I, Bittencourt H, Bertrand Y, Kenzey C, Tozatto Maio K, Hayashi H, Rocha V, Bader P, Gluckman E, Ruggeri A.

Biol Blood Marrow Transplant. 2018 Apr;24(4):799-805. doi: 10.1016/j.bbmt.2017.12.790. Epub 2017 Dec 27.

49.

GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study.

Ansari M, Curtis PH, Uppugunduri CRS, Rezgui MA, Nava T, Mlakar V, Lesne L, Théoret Y, Chalandon Y, Dupuis LL, Schechter T, Bartelink IH, Boelens JJ, Bredius R, Dalle JH, Azarnoush S, Sedlacek P, Lewis V, Champagne M, Peters C, Bittencourt H, Krajinovic M.

Oncotarget. 2017 Aug 27;8(53):90852-90867. doi: 10.18632/oncotarget.20310. eCollection 2017 Oct 31.

50.

Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia.

Kebriaei P, Anasetti C, Zhang MJ, Wang HL, Aldoss I, de Lima M, Khoury HJ, Sandmaier BM, Horowitz MM, Artz A, Bejanyan N, Ciurea S, Lazarus HM, Gale RP, Litzow M, Bredeson C, Seftel MD, Pulsipher MA, Boelens JJ, Alvarnas J, Champlin R, Forman S, Pullarkat V, Weisdorf D, Marks DI; Acute Leukemia Committee of the CIBMTR.

Biol Blood Marrow Transplant. 2018 Apr;24(4):726-733. doi: 10.1016/j.bbmt.2017.11.025. Epub 2017 Dec 25.

Supplemental Content

Loading ...
Support Center